Structure Based Drug Discovery (D6)
Supported by Chiron Corporation
Organizers: Stephen K. Burley, Brian K. Shoichet and Paul A. Bartlett
April 4 - 9, 2006
Fairmont Chateau Whistler
Whistler, British Columbia

http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=771

Meeting Summary

This conference will focus on several exciting new developments in 
Structure Based Drug Discovery, including: fragment based lead 
discovery/lead optimization, high-throughput X-ray and NMR structure 
determination of protein ligand complexes, computational analyses of 
ligand-receptor interactions and prediction of novel ligands, ligand 
binding selectivity, and ADME/toxicity properties. Major/pivotal problems 
facing both academic and industrial scientists include: (a) understanding 
precisely what constitutes a good starting point for lead optimization, 
(b) understanding how best to optimize selectivity and avoid problems 
with ADME/toxicity, (c) understanding the limitations of currently 
available in silico methods, (d) understanding how to combine the results 
of biophysical characterization of protein-ligand interactions with 
medicinal chemistry to produce potent/selective lead compounds, and 
(e) developing sufficient expertise/experience to bring membrane 
proteins and macromolecular interactions within the purview of structure 
based drug discovery. Upon completion of this conference, participants 
should: - Appreciate the challenges represented by membrane proteins 
and macromolecular interactions as targets for structure based drug 
discovery. - Understand current approaches to fragment based drug 
discovery. - Appreciate the state-of-the-art in automated approaches to 
determination of protein-ligand complex structures with solution 
NMR spectroscopy and X-ray crystallography. - Understand the roles 
that homology modeling and computational docking play in structure 
based drug discovery. - Appreciate the contributions that structural 
studies can make to lead optimization and our understanding of 
selectivity and ADME/Toxicity. - Understand the limitations of 
current in silico methods for de novo drug discovery.

Please help: If you find this conference list useful but you noticed some conference missing, please consider including it here by using the Conference Submission Page. It is free but your support is welcome. You will help others!!!